Science 37 raises $31M in series B

12:39 EDT 18 Oct 2016 | BioCentury

Science 37 Inc. (Culver City, Calif.) raised $31 million in a series B financing led by Redmile Group. Existing investors Lux Capital and dRx Capital also participated, as well as Sanofi Genzyme BioVentures.

The company is developing a decentralized approach for conducting clinical trials, which it says will allow sponsors to cut costs through streamlined studies. Using a cloud-based connection platform, Science 37 seeks to replace clinical trial locations with "metasites" that use telemedicine and doctor home visits to give patients access to trials.

Redmile's Rob Faulkner joined Science 37's board.

Original Article: Science 37 raises $31M in series B


More From BioPortfolio on "Science 37 raises $31M in series B"

Quick Search

Relevant Topics

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...